{"id":55580,"date":"2026-01-27T12:32:01","date_gmt":"2026-01-27T04:32:01","guid":{"rendered":"https:\/\/flcube.com\/?p=55580"},"modified":"2026-01-27T12:32:02","modified_gmt":"2026-01-27T04:32:02","slug":"visen-pharma-secures-nmpa-approval-for-skytrofa-in-pediatric-growth-hormone-deficiency","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55580","title":{"rendered":"Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency"},"content":{"rendered":"\n<p><strong>Visen Pharmaceuticals<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2561:HKG\">HKG: 2561<\/a>), a joint venture between <strong>Ascendis Pharma<\/strong> (Denmark) and <strong>Vivo Capital<\/strong>, announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has approved <strong>Skytrofa (lonapegsomatropin, TransCon hGH)<\/strong> for the treatment of <strong>growth failure due to growth hormone deficiency (GHD)<\/strong> in children and adolescents aged <strong>3 years and older<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Visen Pharmaceuticals (JV: Ascendis Pharma \/ Vivo Capital)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Skytrofa (lonapegsomatropin, TransCon hGH)<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>NMPA (China) \u2013 marketing authorization<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Pediatric growth hormone deficiency (GHD)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Children and adolescents \u22653 years with growth failure<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>TransCon (Transient Conjugation) long\u2011acting formulation<\/td><\/tr><tr><td><strong>Dosing<\/strong><\/td><td>Weekly subcutaneous injection vs. conventional daily injections<\/td><\/tr><tr><td><strong>Previous Approvals<\/strong><\/td><td>Registered in Europe and the United States<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-profile-amp-unmet-need\">Clinical Profile &amp; Unmet Need<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease Burden:<\/strong> Pediatric GHD is a serious rare disease where the pituitary gland fails to produce sufficient growth hormone, leading to significant growth failure<\/li>\n\n\n\n<li><strong>Treatment Paradigm Shift:<\/strong> <strong>Lonapegsomatropin<\/strong> transforms the standard of care from <strong>daily<\/strong> to <strong>weekly<\/strong> injections, dramatically reducing treatment burden for pediatric patients and caregivers<\/li>\n\n\n\n<li><strong>TransCon Technology:<\/strong> Proprietary transient conjugation technology enables sustained release of human growth hormone over 7 days while maintaining full biological activity<\/li>\n\n\n\n<li><strong>Clinical Evidence:<\/strong> Pivotal <strong>Phase III trial in China<\/strong> demonstrated <strong>non\u2011inferiority<\/strong> to daily\u2011injected human growth hormone with <strong>comparable safety profile<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-amp-strategic-rights\">Pipeline &amp; Strategic Rights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusive Territory:<\/strong> Visen Pharma holds <strong>exclusive rights<\/strong> for development, manufacturing, and commercialization of Ascendis\u2019s endocrinology pipeline in <strong>Greater China<\/strong><\/li>\n\n\n\n<li><strong>Portfolio Assets:<\/strong> Includes <strong>lonapegsomatropin<\/strong> (Skytrofa), <strong>palopegteriparatide<\/strong>, and <strong>navepegritide<\/strong><\/li>\n\n\n\n<li><strong>Market Position:<\/strong> First long\u2011acting weekly growth hormone approved in China, establishing Visen as leader in pediatric endocrinology<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Pediatric GHD Market:<\/strong> Estimated <strong>\u00a58\u201310\u202fbillion<\/strong> (~US$1.1\u20131.4\u202fbillion) annually, with diagnosis rates increasing due to heightened awareness<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> Weekly dosing offers <strong>significant compliance benefit<\/strong> over daily injections from domestic competitors (GenSci, Anke Biotechnology)<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Expected premium pricing at <strong>\u00a5150,000\u2013200,000<\/strong> per patient annually; NRDL negotiation anticipated for 2027 to expand access<\/li>\n\n\n\n<li><strong>Revenue Forecast:<\/strong> Analysts project <strong>\u00a51.5\u20132.0\u202fbillion<\/strong> (US$210\u2013280\u202fmillion) peak annual sales by 2029, capturing 15\u201320% market share<\/li>\n\n\n\n<li><strong>Launch Timeline:<\/strong> Commercial availability expected <strong>Q2\u202f2026<\/strong> via specialty pharmacy and hospital channels<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial expectations, market penetration, and revenue projections for Skytrofa in China. Actual results may differ due to pricing negotiations, competitive dynamics, and reimbursement decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026012601063_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026012601063_c.\"><\/object><a id=\"wp-block-file--media-45829d1f-a254-4030-8b47-91e36efc18a8\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026012601063_c.pdf\">2026012601063_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026012601063_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-45829d1f-a254-4030-8b47-91e36efc18a8\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Visen Pharmaceuticals (HKG: 2561), a joint venture between Ascendis Pharma (Denmark) and Vivo Capital, announced&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55582,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[392,4363,15,393],"class_list":["post-55580","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-ascendis-pharma","tag-hkg-2561","tag-product-approvals","tag-visen-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Visen Pharmaceuticals (HKG: 2561), a joint venture between Ascendis Pharma (Denmark) and Vivo Capital, announced that China\u2019s National Medical Products Administration (NMPA) has approved Skytrofa (lonapegsomatropin, TransCon hGH) for the treatment of growth failure due to growth hormone deficiency (GHD) in children and adolescents aged 3 years and older.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55580\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency\" \/>\n<meta property=\"og:description\" content=\"Visen Pharmaceuticals (HKG: 2561), a joint venture between Ascendis Pharma (Denmark) and Vivo Capital, announced that China\u2019s National Medical Products Administration (NMPA) has approved Skytrofa (lonapegsomatropin, TransCon hGH) for the treatment of growth failure due to growth hormone deficiency (GHD) in children and adolescents aged 3 years and older.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55580\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-27T04:32:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-27T04:32:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2703.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55580#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55580\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency\",\"datePublished\":\"2026-01-27T04:32:01+00:00\",\"dateModified\":\"2026-01-27T04:32:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55580\"},\"wordCount\":385,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55580#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2703.webp\",\"keywords\":[\"Ascendis Pharma\",\"HKG: 2561\",\"Product approvals\",\"Visen Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55580#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55580\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55580\",\"name\":\"Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55580#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55580#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2703.webp\",\"datePublished\":\"2026-01-27T04:32:01+00:00\",\"dateModified\":\"2026-01-27T04:32:02+00:00\",\"description\":\"Visen Pharmaceuticals (HKG: 2561), a joint venture between Ascendis Pharma (Denmark) and Vivo Capital, announced that China\u2019s National Medical Products Administration (NMPA) has approved Skytrofa (lonapegsomatropin, TransCon hGH) for the treatment of growth failure due to growth hormone deficiency (GHD) in children and adolescents aged 3 years and older.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55580#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55580\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55580#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2703.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2703.webp\",\"width\":1080,\"height\":608,\"caption\":\"Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55580#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency - Insight, China&#039;s Pharmaceutical Industry","description":"Visen Pharmaceuticals (HKG: 2561), a joint venture between Ascendis Pharma (Denmark) and Vivo Capital, announced that China\u2019s National Medical Products Administration (NMPA) has approved Skytrofa (lonapegsomatropin, TransCon hGH) for the treatment of growth failure due to growth hormone deficiency (GHD) in children and adolescents aged 3 years and older.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55580","og_locale":"en_US","og_type":"article","og_title":"Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency","og_description":"Visen Pharmaceuticals (HKG: 2561), a joint venture between Ascendis Pharma (Denmark) and Vivo Capital, announced that China\u2019s National Medical Products Administration (NMPA) has approved Skytrofa (lonapegsomatropin, TransCon hGH) for the treatment of growth failure due to growth hormone deficiency (GHD) in children and adolescents aged 3 years and older.","og_url":"https:\/\/flcube.com\/?p=55580","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-27T04:32:01+00:00","article_modified_time":"2026-01-27T04:32:02+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2703.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55580#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55580"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency","datePublished":"2026-01-27T04:32:01+00:00","dateModified":"2026-01-27T04:32:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55580"},"wordCount":385,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55580#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2703.webp","keywords":["Ascendis Pharma","HKG: 2561","Product approvals","Visen Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55580#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55580","url":"https:\/\/flcube.com\/?p=55580","name":"Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55580#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55580#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2703.webp","datePublished":"2026-01-27T04:32:01+00:00","dateModified":"2026-01-27T04:32:02+00:00","description":"Visen Pharmaceuticals (HKG: 2561), a joint venture between Ascendis Pharma (Denmark) and Vivo Capital, announced that China\u2019s National Medical Products Administration (NMPA) has approved Skytrofa (lonapegsomatropin, TransCon hGH) for the treatment of growth failure due to growth hormone deficiency (GHD) in children and adolescents aged 3 years and older.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55580#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55580"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55580#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2703.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2703.webp","width":1080,"height":608,"caption":"Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55580#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2703.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55580","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55580"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55580\/revisions"}],"predecessor-version":[{"id":55583,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55580\/revisions\/55583"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55582"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55580"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55580"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}